The Emirates called for strengthening the international humanitarian response and providing urgent relief to those in need
mena3 hours ago
The US Food and Drug Administration on Monday granted emergency approval to a synthetic antibody treatment against Covid-19 developed by Eli Lilly, after the drug was shown to reduce the risk of hospitalization and emergency room visits.
Bamlanivimab at a dose of 700 milligrams was authorized for the treatment of mild-to-moderate Covid-19 in adults and children aged 12 years and older who are at high risk for progressing to the severe form of the disease.
It is the first drug to be approved that was designed specifically against the new coronavirus.
“As illustrated by today’s action, the FDA remains committed to expediting the development and availability of potential COVID-19 treatments,” said the agency’s chief Stephen Hahn.
The approval was based on a mid-stage clinical trial for outpatients with mild to moderate Covid-19, where the intravenous treatment was shown to reduce viral loads and rates of symptoms and hospitalization.
The FDA said in its statement that the most important evidence that bamlanivimab may be effective came from data that showed that among patients at high risk of severe disease, hospitalizations and emergency room visits occurred in 3 percent of bamlanivimab-treated patients compared to 10 percent who were on the placebo.
The frequency and types of side effects were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity.
The most common were diarrhea, dizziness, headache, itchiness and vomiting.
The trial is ongoing and aims to enroll more than 800 patients across various dosage groups.
An important caveat is that bamlanivimab has not been authorized for patients who are hospitalized — since no benefit has been shown for patients who are already in this late stage of the disease, when the body’s immune defenses go into overdrive and damage organs.
The FDA wrote that administering the drug too late could be associated with worse outcomes, and a trial exploring bamlanivimab in hospitalized patients was suspended last month over a safety incident.
Bamlanivimab is what’s known as a monoclonal antibody, a relatively new class of drugs that are best known for treating certain types of cancer and autoimmune disease.
Human immune systems produce antibodies, which are infection-fighting proteins, and vaccines teach our bodies to be prepared to make the right ones for particular pathogens.
Bamlanivimab was based on an effective antibody Lilly found in a recovered patient.
The host immune cells that produce the antibodies can be cultured in a lab to produce the desired proteins en masse.
It works by binding to a surface protein of the coronavirus to stop it from invading human cells.
The Emirates called for strengthening the international humanitarian response and providing urgent relief to those in need
mena3 hours ago
Photonics is the study of light and has several applications including LED, VR, holograms, high-speed internet and solar panels among other things
uae3 hours ago
A delegation from Egypt arrived in Israel on Friday hoping to revive the truce negotiations
mena3 hours ago
The decision aims to protect the safety and security of pilgrims
gulf4 hours ago
They have been carrying out rescue operations for the last four years, drawing on their extensive experience in saving people from desert terrain
uae4 hours ago
Dubai Amateur 17-year-old Oscar Craig continues to showcase his impressive form with third-round level par 72 at Saadiyat Beach Golf Club
sports5 hours ago
The tragic incident led to the death of a number of innocent people from Yemen
mena5 hours ago
Alongside regional leaders, US Secretary of State Antony Blinken will attend the meetings
world5 hours ago